Angiotensin II, Aldosterone, Oxidation, and CaMKII in Hypertrophy and Arrhythmias
Angiotensin II, Aldosterone, Oxidation, and CaMKII in Hypertrophy and Arrhythmias
批准号:
7496062
负责人:
MARK E ANDERSON
金额:
$35.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-23 至 2010-07-31
关键词:
Adrenergic ReceptorAldosteroneAmino AcidsAngiotensin IIAngiotensinsApoptosisApoptoticAppendixArrhythmiaAutomobile DrivingBuffersCalcium/calmodulin-dependent protein kinaseCalmodulinCardiacCardiac MyocytesCessation of lifeComplementConditionDataDiseaseDominant-Negative MutationExhibitsFigs - dietaryFunctional disorderHandHeartHeart DiseasesHeart HypertrophyHeart failureHistone DeacetylaseHypertrophyIn VitroInfusion proceduresKnowledgeLaboratoriesLinkMeasuresMethodsModificationMolecularMultienzyme ComplexesMusMutagenesisMyocardialMyocardial InfarctionNADPH OxidaseNF-kappa BNodalOutcomeOxidantsPatientsPeptidesPharmaceutical PreparationsPhenotypePhosphotransferasesPhysiologicalProteinsProteomicsReactive Oxygen SpeciesReagentReceptor SignalingReninReporterRepressionResearch PersonnelRoleSignal PathwaySignal TransductionSourceStressTestingUnited StatesWorkcalmodulin-dependent protein kinase IIclinical phenotypeimproved functioningin vivoinhibitor/antagonistinnovationmouse modelmouse p47noveloxidationpreventprogramsresearch studyresponsetranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Heart failure and arrhythmias are among the most significant causes of premature death in the United States. Activation of renin-angiotensin (Angll)-aldosterone (Aldo) signaling (RAAS) is a common feature of structural heart disease that leads to heart failure and is associated with arrhythmias. Drugs that inhibit RAAS are cornerstones for reducing death in heart failure patients, but the specific 'downstream' cellular signals that are activated by RAAS and represent the proximate cause of adverse structural and pro- arrhythmic electrical remodeling in heart failure are incompletely understood. RAAS causes increased oxidant stress and may increase cellular Ca2+. Our group has found that RAAS causes increased activity of the multifunctional Ca2+/calmodulin-dependent protein kinase II (CaMKII) and that CaMKII inhibition prevents or significantly reduces cardiac hypertrophy during RAAS. CaMKII has recently emerged as a pathological signal in heart failure and arrhythmias, and these findings mark CaMKII as a previously unrecognized but necessary signal for pathological RAAS. We have developed evidence that RAAS can activate CaMKII by cellular Ca2+ mobilization (a conventional mechanism) and by a novel, previously unidentified mechanism involving oxidant modification of susceptible amino acid residues in the CaMKII regulatory domain. NADPH oxidase is an enzyme complex that generates reactive oxygen species (ROS) during RAAS, and our preliminary findings suggest that NADPH oxidase is required for maximal CaMKII activity during RAAS. We will answer key questions posed in response to these preliminary findings using the following Specific Aims: 1. Determine the mechanism for CaMKII activation by Angll 2. Determine the role of Angll signaling through NF-kB and MEF2 3. Determine the role of CaMKII in Aldo signaling. The proposed studies will provide critically needed new knowledge of the mechanistic links between RAAS and important clinical phenotypes of cardiac hypertrophy, dysfunction and arrhythmias.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CaMKII signaling in physiology, heart failure and arrhythmias
-
批准号:10335191
-
项目类别:
-
资助金额:$96.36万
-
财政年份:2018
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII signaling in physiology, heart failure and arrhythmias
-
批准号:10077577
-
项目类别:
-
资助金额:$119.86万
-
财政年份:2018
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII signaling in physiology, heart failure and arrhythmias
-
批准号:10026490
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2018
-
负责人:MARK E ANDERSON
-
依托单位:
2014 Cardiac Regulatory Mechanisms Gordon Research Conference & Gordon Research S
-
批准号:8784793
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
Mitochondrial Calmodulin Kinase II in Physiology and Disease
-
批准号:8909894
-
项目类别:
-
资助金额:$39.69万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:9115686
-
项目类别:
-
资助金额:$38.79万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8909874
-
项目类别:
-
资助金额:$39.53万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8915241
-
项目类别:
-
资助金额:$38.21万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
Mitochondrial Calmodulin Kinase II in Physiology and Disease
-
批准号:8915239
-
项目类别:
-
资助金额:$39.22万
-
财政年份:2014
-
负责人:MARK E ANDERSON
-
依托单位:
2012 Cardiac Regulatory Mechanisms Gordon Research Conference and Gordon Research
-
批准号:8316613
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8628170
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8812901
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8271667
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
Oxidized CaMKII in Atrial Fibrillation
-
批准号:8449636
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2012
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:7695210
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8575675
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8056075
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
CaMKII in Sinus Node Physiology and Disease
-
批准号:8269846
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
TESTING AND CALIBRATION OF SPECTROMETER FUNCTIONS
-
批准号:7954631
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
RUNNING POSSIBLE COLLABORATORY EXPERIMENTS
-
批准号:7954627
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2009
-
负责人:MARK E ANDERSON
-
依托单位:
海外基金